Sensei Biotherapeutics is a clinical-stage biotechnology company developing therapies to improve cancer outcomes through multi-node inhibition of key oncogenic pathways. The company's lead program, PIKTOR, is an investigational oral combination therapy targeting the PI3K/AKT/mTOR pathway—dysregulated in roughly half of all solid tumors—for use in endometrial and breast cancer; the company believes simultaneously inhibiting multiple pathway nodes produces deeper and more durable tumor suppression with improved tolerability compared to single-node approaches. Revenue generation depends on the successful development and eventual commercialization of these therapies, supported by intellectual property licenses from established pharmaceutical partners.